Edgewise Therapeutics, Inc. Common Stock
EWTXEdgewise Therapeutics, Inc. is a biotechnology company focused on developing small-molecule therapies for rare and underserved genetic muscle disorders. The company utilizes a deep understanding of muscle biology to identify and develop targeted treatments aimed at improving muscle function and quality of life for patients with these conditions.
Company News
Edgewise Therapeutics stock surged nearly 26% on December 23rd after the biotech presented positive interim Phase 2 clinical trial data for EDG-7500, an investigational drug targeting hypertrophic cardiomyopathy (HCM). The drug showed clinical activity across significant disease markers, maintained a favorable safety profile, and exceeded year-en...
Pomerantz Law Firm is investigating potential securities fraud by Edgewise Therapeutics after the company reported clinical trial results that were deemed insufficient for accelerated FDA approval, causing a stock price drop.
Pomerantz Law Firm is investigating potential securities fraud at Edgewise Therapeutics after the company reported clinical trial results that were deemed insufficient for accelerated FDA approval, causing a stock price drop.
Edgewise Therapeutics' (EWTX) share price surged 50% in a single session due to positive results from early trials of its novel treatment for obstructive hypertrophic cardiomyopathy, a leading cause of sudden cardiac-related death in young people. The company's pipeline and strong financial position also contribute to the positive sentiment.
Bausch & Lomb and Edgewise Therapeutics were among the top 7 mid-cap stock gainers last week, with Edgewise Therapeutics shares rocketing 50.19% after announcing positive topline data from a clinical trial, and Bausch & Lomb's parent company Bausch Health considering a sale.
